Clinical Trials Directory

Trials / Conditions / Nodal Marginal Zone Lymphoma

Nodal Marginal Zone Lymphoma

17 registered clinical trials studyying Nodal Marginal Zone Lymphoma — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingEpcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
NCT06796998
Izidore Lossos, MDPhase 2
RecruitingIntegrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Noda
NCT05700149
International Extranodal Lymphoma Study Group (IELSG)—
RecruitingStudy of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Schrödinger, Inc.Phase 1
RecruitingStudy of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapse
NCT04223765
UNC Lineberger Comprehensive Cancer CenterPhase 1
Active Not RecruitingMALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT03697512
International Extranodal Lymphoma Study Group (IELSG)Phase 2
CompletedSalvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
NCT02652715
Mayo ClinicN/A
TerminatedIbrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
NCT02109224
National Cancer Institute (NCI)Phase 1
CompletedAlisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C
NCT01567709
National Cancer Institute (NCI)Phase 1
CompletedSafety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
NCT01701232
BiocadPhase 3
CompletedVeliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma
NCT01326702
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedLenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
NCT01254578
National Cancer Institute (NCI)Phase 1
CompletedDasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg
NCT00608361
National Cancer Institute (NCI)Phase 1
CompletedRituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Lo
NCT00711828
Mayo ClinicPhase 2
CompletedVorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
NCT00253630
National Cancer Institute (NCI)Phase 2
CompletedAgatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Ref
NCT00438880
Mayo ClinicPhase 1 / Phase 2
CompletedTipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00082888
National Cancer Institute (NCI)Phase 2
CompletedBortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
NCT00082784
National Cancer Institute (NCI)Phase 1